HBS Biopharma

HBS Biopharma is a biotechnology company focused on developing targeted therapies for liver diseases, specifically focusing on Hepatitis B virus (HBV) related conditions. The company's lead research centers on the inhibition of the HBV X protein (HBx), which plays a critical role in viral replication and the development of hepatocellular carcinoma. By targeting the underlying mechanisms of viral persistence and oncogenesis, HBS Biopharma aims to provide curative options for chronic HBV patients. The company is currently in the pre-clinical stage of development, advancing its small molecule candidates toward regulatory filings.